Pharvaris publishes patient-reported outcomes presentation on clinical evidence in HAE trials

• Pharvaris published a medical research presentation on patient-reported outcomes shaping clinical evidence in hereditary angioedema drug development.
• Slides flagged orphan-drug timelines: median FDA review 244 days; median development 7.2 years; median EMA review 353 days.
• RAPIDe-1 data showed deucrictibant immediate-release met the primary endpoint, reducing AMRA-3 attack symptoms at 4 hours versus placebo across 10 mg–30 mg doses.
• FDA feedback in the deck pointed to a global endpoint such as PGI-C as potentially more interpretable for primary outcomes.
• RAPIDe-3 was presented as a Phase 3 on-demand HAE trial design incorporating contemporaneous post-attack patient interviews to support endpoint selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.